pediatric-pathology-and-laboratory-medicine-2017_keynote

11 / 14

Volume 7, Issue 1 (Suppl) J Clin Exp Pathol
ISSN: 2161-0681 JCEP, an open access journal
Pediatric Pathology & Laboratory Medicine 2017
March 15-16, 2017
Page 46
Notes:
conferenceseries.com
March 15-16, 2017 London, UK
12th International Conference on
Pediatric Pathology & Laboratory Medicine
Neuroleptic-induced oral-facial tardive dyskinesia in a prepuberal boy with an attention-deficit
hyperactivity disorder
Introduction & Aim: The use of antipsychotics, antagonists of dopamine D2 receptors in the treatment of ADHD in children
needs further revision given the incidence of side effects of unknown frequency as tardive dyskinesia and acute extrapyramidal
symptoms, both induced by haloperidol and the fact that overdose can produce dangerous morbidity, sometimes even
requiring intensive care treatment. Patients receiving neuroleptics such as butyrophenone haloperidol for a long period of
time can develop several forms of a rare side effect included among the extrapyramidal dyskinetic syndromes, especially oral-
facial involuntary movements as well as uncontrolled movements of the extremities called tardive dyskinesia. In this study, we
present a case of Tardive dyskinesia, the most frequent group of involuntary movements in patient taking haloperidol.
Case Report: An 11-year-old male patient taking a high dose of haloperidol and methylphenidate in a normal dose for
two years was hospitalized due to the severity of the symptoms and eventually the child developed a syndrome of Tardive
dyskinesia. Upon admission, medication was stopped and the symptoms disappeared in the next 24 hours. Three days later
the boy recovered completely and was discharged from the hospital to follow treatment in the outpatient clinic. There were no
recurrences of the Dyskinetic reactions during that summer.
Conclusions: Given the possibility of presentation of Tardive dyskinesia and other acute extrapyramidal symptoms, we strongly
recommend avoiding the prescription of haloperidol, especially associated to methylphenidate (also responsible for some cases
of Tardive dyskinesia) in the treatment of attention-deficit hyperactivity disorder (ADHD).
Biography
María Amparo Lopez-Ruiz has completed her PhD from Valencia University and Post-doctoral studies from the CEU Cardenal Herrera University. She completed
her Doctorate in Medicine with thesis entitled: Analysis of the use of medication in the pediatric population that visits accident and emergency department. She has
been a Medical Degree Coordinator at CEU Cardenal Herrera University since 2015. She has attended international congresses of pediatrics as a Keynote Speaker
and has published more than 20 papers in reputed journals.
María Amparo Lopez-Ruiz
CEU Cardenal Herrera University, Spain
María Amparo Lopez-Ruiz, J Clin Exp Pathol 2017, 7:1 (Suppl)